September 2016

Prostate Tumors May Not Be Immunologic, Says Expert

October 03, 2016

Clinical Articles

Although prostate cancer was among the first tumor types to be studied with immunotherapy treatments, prostate cancer appears to not be immunologic, according to Susan F. Slovin, MD, PhD.

SITC's Consensus Statements Guide the Integration of Immunotherapy Treatment Into Practice

October 05, 2016

Clinical Articles

As new drugs and combinations gain approvals for a broad range of malignancies, there is a growing need for disease-specific recommendations to help guide the integration of immunotherapy treatments into current practice.

Immunotherapies Combined With Lung Cancer Treatments Could Be Practice Changing

October 06, 2016

Clinical Articles

Recent randomized clinical trials that have combined immunotherapy with chemotherapy, molecular therapy, or anti-angiogenic therapy for the treatment of patients with lung cancer have shown promising results for these combinations.

Multiplex Genetic Testing Overtaking Single-Gene Assays

October 06, 2016

Clinical Articles

Lynette M. Sholl, MD, discusses advancements in molecular diagnostics that have led to the development of numerous single-gene assays for the detection of genetic mutations that can be targeted in the treatment of cancers.

Debating Molecular Markers in the Treatment of DLBCL

October 07, 2016

Clinical Articles

Two oncologists from Emory University School of Medicine faced off to determine if molecular markers should play a role in the treatment of subgroups of patients with diffuse large B-cell lymphoma.

Closing In on TP53 Mutations in Lung Cancer

October 19, 2016

Clinical Articles

Although there are no drugs yet that target TP53 mutations in any tumor type, a recent analysis of a non–small cell lung cancer (NSCLC) sample set raises the prospect that a more detailed understanding of this aberration could eventually help direct therapy.

PER to Host New European Conferences

October 19, 2016

Clinical Articles

For the first time, Physicians’ Education Resource (PER®) will host 2 European conferences, providing more opportunities for oncology professionals worldwide to learn and collaborate with leading experts in the fields.

CVS Cuts Out In-House Dispensaries of Cancer Drugs

October 20, 2016

Clinical Articles

A move by CVS Health to place in-house physician dispensaries out-of-network for purposes of Medicare Part D drug payment would force hundreds of thousands of cancer patients across the country to find alternate sources for their oral oncolytic drugs, the Community Oncology Alliance (COA) argued in a new white paper.